Drug intelligence / Profile preview

Oxygen + nitrous oxide

Development stage
Phase 3
Lead developer
Linde
Modality
Small Molecules
Administration
Inhalation
01

Overview

Oxygen + nitrous oxide is a fixed-ratio combination medical gas, typically containing 50% nitrous oxide and 50% oxygen. It is administered via inhalation for its analgesic (pain-relieving) and anxiolytic (anxiety-reducing) effects. The mixture acts rapidly—onset within about 30 seconds—and the effects last for approximately one minute after cessation. Nitrous oxide functions primarily as an N-methyl-D-aspartate (NMDA) receptor antagonist in the central nervous system, producing dissociative anesthesia and analgesia while maintaining consciousness at sub-anesthetic doses. Oxygen ensures adequate tissue oxygenation during administration of nitrous oxide, which can otherwise displace atmospheric oxygen in the lungs. This combination is widely used for short-term pain relief during procedures such as childbirth, dental work, trauma care, and minor surgical interventions[5]. It is also used in emergency medicine settings due to its rapid onset and offset of action[5]. The product is supplied under various brand names such as Entonox or Nitronox[5].

Brand names
EntonoxNitronox
Other names
laughing gas and oxygen50% nitrous oxide/50% oxygen mixture
02

Targets

iGluR (Ionotropic receptor 76b (Ir76b))AChR (Acetylcholine receptor)ADRA2A (α2A)GABRR (GABA-A receptor subunit rho)Glycine receptorH (Histamine receptors)NMDAR (N-methyl-D-aspartate receptor)MOR (Mu opioid receptor)KCNK2 (Potassium channel subfamily K member 2)NMDAR (Glutamate receptor ionotropic, NMDA)

Beyond the preview

Go deeper on Oxygen + nitrous oxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxygen + nitrous oxide.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call